The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APVO | -99.11% | -100% | -90.76% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +210% |
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.05M | 46.2% |
| Market Cap | $9.83M | 4671.3% |
| Market Cap / Employee | $0.23M | 0.0% |
| Employees | 42 | 5.0% |
| Net Income | -$6.20M | -5.5% |
| EBITDA | -$6.18M | -4.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.41M | 16.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.21M | -16.2% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -157.31% | -42.1% |
| Return On Invested Capital | -109.88% | 5.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.09M | -15.3% |
| Operating Free Cash Flow | -$7.09M | -15.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.69 | 1.32 | -1.15 | -0.15 | -546.75% |
| Price to Tangible Book Value | 121.65 | 8.99 | 7.12 | -0.15 | -100.60% |
| Enterprise Value to EBITDA | 0.20 | -0.35 | -0.62 | 0.48 | 44.26% |
| Return on Equity | -251.0% | -284.3% | -1023.9% | -437.3% | 79.42% |
| Total Debt | $4.83M | $4.63M | $4.42M | $4.21M | -16.24% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
